Email this article Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease
- Authors: Solovyev MV1, Mendeleeva LP1, Pokrovskaya OS1, Nareyko MV1, Firsova MV2, Galtseva IV1, Davydova Y.O1, Kapranov NM1, Kuzmina LA1, Gemdzhian EG1, Savchenko VG1
-
Affiliations:
- ФГБУ «Гематологический научный центр» Минздрава России
- ФФГБУ «Гематологический научный центр» Минздрава России
- Issue: Vol 89, No 7 (2017)
- Pages: 25-31
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32258
- DOI: https://doi.org/10.17116/terarkh201789725-31
- ID: 32258
Cite item
Full Text
Abstract
Aim. To determine the efficiency of maintenance therapy with bortezomib in patients with multiple myeloma (MM) who have achieved complete remission (CR) after autologous hematopoietic stem cell (auto-HSCT), depending on the presence of minimal residual disease (MRD). Subjects and methods. In January 2014 to February 2016, fifty-two MM patients (19 men and 33 women) aged 24 to 66 years (median 54 years), who had achieved CR after auto-HSCT, were randomized to perform maintenance therapy with bortezomib during a year. On day 100 after auto-HSCT, all the patients underwent immunophenotyping of bone marrow plasma cells by 6-color flow cytometry to detect MRD. Relapse-free survival (RFS) was chosen as a criterion for evaluating the efficiency of maintenance therapy. Results. After auto-HSCT, MRD-negative patients had a statistically significantly higher 2-year RFS rate than MRD-positive patients: 52.9% (95% confidence interval (CI), 35.5 to 70.5%) versus 37.2% (95% CI, 25.4 to 49.3%) (p=0.05). The presence of MRD statistically significantly increased the risk of relapse (odds ratio 1.7; 95% CI, 1.2 to 3.4; p=0.05). Two-year cumulative risk of relapse (using the Kaplan-Meier) after auto-HSCT did not statistically significantly differ in MRD-negative patients receiving (n=15) and not receiving (n=10) maintenance therapy with bortezomib (p=0.58). After completion of maintenance treatment, 42% of the MRD-positive patients achieved a negative status. In the MRD-positive patients who had received maintenance therapy, the average time to recurrence was 5 months longer than that in the naïve patients: 17.3 versus 12.3 months. Conclusion. The MRD status determined in MM patients who have achieved CR after auto-HSCT is an important factor for deciding on the use of maintenance therapy.
Full Text
##article.viewOnOriginalSite##About the authors
M V Solovyev
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
L P Mendeleeva
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
O S Pokrovskaya
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
M V Nareyko
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
M V Firsova
ФФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
I V Galtseva
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
Yu O Davydova
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
N M Kapranov
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
L A Kuzmina
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
E G Gemdzhian
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
V G Savchenko
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
References
- Prashant Kapoor, Shaji K Kumar, Angela Dispenzieri, Martha Q Lacy, Francis Buadi, David Dingli, Stephen J Russell, Suzanne R Hayman, Thomas E Witzig, John A Lust, Nelson Leung, Yi Lin, Steven R Zeldenrust, Arleigh McCurdy, Philip R Greipp, Robert A Kyle, S Vincent Rajkumar, and Morie A Gertz. Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology. 2013;31(36):4529-4535. https://doi.org/10.1200/JCO.2013.49.0086
- Nooka A, Kaufman J, Lonial S. The importance of complete response in outcomes in myeloma. The Cancer Journal. 2009; 15(6):465-472. https://doi.org/10.1097/PPO.0b013e3181c51cd4
- Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, Komarnicki M, Mateos MV, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 2010;116(19):3743-3750. https://doi.org/10.1182/blood-2010-03-275800
- Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. Journal of Clinical Oncology. 2008;26(35):5775-5782. https://doi.org/10.1200/JCO.2008.17.9721
- Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P; Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. Journal of Clinical Oncology. 2005;23(36):9227-9233. https://doi.org/10.1200/JCO.2005.03.0551
- Michel Attal, Valerie Lauwers-Cances, Cyrille Hulin, Thierry Facon, Denis Caillot, Martine Escoffre, Bertrand Arnulf, Margaret MACRO, Karim Belhadj, Laurent Garderet, Murielle Roussel, Claire Mathiot, Herve Avet-Loiseau, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, jean Luc Harousseau and Philippe Moreau. Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood. 2015;126(23):391.
- Dadvid Cunningham, Ray Powles, James Malpas, Noopur Raje, Sarah Milan, Christine Viner, Anna Montes, Tamas Hickish, Marianne Nicolson, Paul Johnson, Jennifer Treleaven, Julian Raymond, Martin Gore. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. British Journal of Haematology. 1998;102(2):495-502. https://doi.org/10.1046/j.1365-2141.1998.00795.x
- Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. The American Journal of Hematology. 2000;65(3):204-209. https://doi.org/10.1002/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H
- Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013; 121(23):4647-4654. https://doi.org/10.1182/blood-2012-11-464503
- Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Journal of Clinical Oncology. 2012;30(24):2946-2955. https://doi.org/10.1200/jco.2011.39.6820
- Bart Barlogie, Robert A Kyle, Kenneth C Anderson, Philip R Greipp, Hillard M Lazarus, David D Hurd, Jason McCoy, Shaker R Dakhil, Keith S Lanier, Robert A Chapman, Jeana N Cromer, Sydney E Salmon, Brian Durie, John C Crowley. Standard hemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. Journal of Clinical Oncology. 2006;24(6):929-936. https://doi.org/10.1200/jco.2005.04.5807
- Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P; Panel on Clinical Endpoints in Multiple Myeloma. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231-239. https://doi.org/10.1038/sj.leu.2405016
- Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine. 2003;8;348(19):1875-1883. https://doi.org/1056/nejmoa022340
- Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. The New England Journal of Medicine. 1996;335(2):91-97. https://doi.org/10.1056/nejm199607113350204
- Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. The New England Journal of Medicine. 2003;349(26):2495-2502. https://doi.org/10.1056/nejmoa032290
- Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. The New England Journal of Medicine. 2012;366(19):1782-1791. https://doi.org/10.1056/nejmoa1114138
- Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012; 120(8):1589-1596. https://doi.org/10.1182/blood-2012-02-408922
- Bruno Paiva, Maria-Belén Vidriales, Jorge Cerveró, Gema Mateo, Jose J. Pérez, Maria A. Montalbán, Anna Sureda, Laura Montejano, Norma C. Gutiérrez, Alfonso García de Coca, Natalia de las Heras, Maria V. Mateos, Maria C. López-Berges, Raimundo García-Boyero, Josefina Galende, Jose Hernández, Luis Palomera, Dolores Carrera, Rafael Martínez, Javier de la Rubia, Alejandro Martín, Joan Bladé, Juan J. Lahuerta, Alberto Orfao, and Jesús F. San Miguel. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Вlood. 2008;112:4017-4023. https://doi.org/10.1182/blood-2008-05-159624
- S. Vincent Rajkumar. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2016;35:418-423. https://doi.org/10.14694/EDBK_159009
- Менделеева Л.П., Вотякова О.М., Покровская О.С., Рехтина И.Г., Дарская Е.И., Гальцева И.В., Капланов К.Д., Моторин Д.В., Самойлова О.С., Семочкин С.В., Скворцова Н.В., Соловьев М.В., Урнова Е.С., Савченко В.Г. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология. 2016;1S(2):1-24. https://doi.org/10.18821/0234-5730-2016-61-1(Прил. 2)
- Maryalice Stetler-Stevenson, Bruno Paiva, Lloyd Stoolman, Pei Lin, Jeffrey L. Jorgensen, Alberto Orfao, Jacques Van Dongen, and Andy C. Rawstron. Consensus Guidelines for Myeloma Minimal Residual Disease Sample Staining and Data Acquisition. Clinical Cytometry. 2016;90(1):26-30. https://doi.org/10.1002/cyto.b.21249
- Vincent T DeVita, Jr, Samuel Hellman, Steven A Rosenberg, eds. Philadelphia:Lippincott-Raven Publishers. Cancer: Principles and Practice of Oncology. Journal of the National Cancer Institute. 1997:3125. https://doi.org/10.1093/jnci/89.6.353
- Maxim V Solovev, Larisa P Mendeleeva, Olga S Pokrovskaya, Eduard G Gemdzhian, Larisa A Kuzmina, Maya Firsova, Irina Galtseva, Julia Davydova and Valeri G Savchenko. Maintenance Therapy after Autologous Haematopoietic Stem Cell Transplantation (auto-HSCT) in Multiple Myeloma Patients with and without Minimal Residual Disease (MRD). Blood. 2016;128:2260.
- Осипов Ю.С., Афанасьев Б.В., Дарская Е.И., Бабенко Е.И., Марами-Зонузи Н.Э, Вавилов В.Н., Эстрина М.А. Роль мониторинга MRD у больных множественной миеломой в определении тактики поддерживающей терапии. Гематология и трансфузиология. 2014;1(59):57.
